Aldeyra Therapeutics Inc (NASDAQ:ALDX) shares, rose in value on Wednesday, April 16, with the stock price down by -8.64% to the previous day’s close as strong demand from buyers drove the stock to $2.01.
Actively observing the price movement in the last trading, the stock closed the session at $2.20, falling within a range of $1.99 and $2.23. The value of beta (5-year monthly) was 0.928. Referring to stock’s 52-week performance, its high was $7.20, and the low was $1.14. On the whole, ALDX has fluctuated by -69.84% over the past month.
With the market capitalization of Aldeyra Therapeutics Inc currently standing at about $120.02 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-27.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach -666.67k.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ALDX’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 50% Buy while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the price of ALDX currently trading nearly -50.75% and -63.16% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 26.43, while the 7-day volatility ratio is showing 10.92% which for the 30-day chart, stands at 15.35%. Furthermore, Aldeyra Therapeutics Inc (ALDX)’s beta value is 1.06, and its average true range (ATR) is 0.55.
A comparison of Aldeyra Therapeutics Inc (ALDX) with its peers suggests the former has fared considerably weaker in the market. ALDX showed an intraday change of -8.64% in last session, and over the past year, it shrunk by -51.68%%.
Data on historical trading for Aldeyra Therapeutics Inc (NASDAQ:ALDX) indicates that the trading volumes over the past 10 days have averaged 5.56 and over the past 3 months, they’ve averaged 1.44 million. According to company’s latest data on outstanding shares, there are 59.65 million shares outstanding.
Nearly 2.90% of Aldeyra Therapeutics Inc’s shares belong to company insiders and institutional investors own 55.52% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 3.55 million shares as on 2025-03-31, resulting in a short ratio of 3.87. According to the data, the short interest in Aldeyra Therapeutics Inc (ALDX) stood at 715.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 3.61 million. The stock has fallen by -59.72% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ALDX stock heading into the next quarter.
